TANI, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 2.716
AS - Asia 2.333
EU - Europa 1.763
AF - Africa 143
SA - Sud America 98
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.059
Nazione #
US - Stati Uniti d'America 2.670
VN - Vietnam 787
SG - Singapore 558
CN - Cina 546
GB - Regno Unito 447
SE - Svezia 337
DE - Germania 222
IT - Italia 200
HK - Hong Kong 147
FR - Francia 111
UA - Ucraina 96
IN - India 83
RU - Federazione Russa 77
IE - Irlanda 67
BR - Brasile 61
CI - Costa d'Avorio 45
JO - Giordania 40
JP - Giappone 38
ZA - Sudafrica 37
NL - Olanda 34
HR - Croazia 31
FI - Finlandia 28
CA - Canada 27
KR - Corea 26
TG - Togo 26
EE - Estonia 25
CH - Svizzera 20
PH - Filippine 19
BE - Belgio 16
AR - Argentina 15
PL - Polonia 14
IR - Iran 12
NG - Nigeria 12
TW - Taiwan 11
BD - Bangladesh 10
ES - Italia 10
TR - Turchia 10
BG - Bulgaria 9
SC - Seychelles 9
TH - Thailandia 9
EC - Ecuador 8
ID - Indonesia 8
MX - Messico 8
GR - Grecia 6
UZ - Uzbekistan 5
AT - Austria 4
IQ - Iraq 4
MA - Marocco 4
TN - Tunisia 4
BO - Bolivia 3
CL - Cile 3
IL - Israele 3
KE - Kenya 3
LB - Libano 3
SA - Arabia Saudita 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
CO - Colombia 2
LK - Sri Lanka 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PK - Pakistan 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
AG - Antigua e Barbuda 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LT - Lituania 1
NO - Norvegia 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
UY - Uruguay 1
Totale 7.059
Città #
Singapore 399
Southend 382
Fairfield 254
Ashburn 252
Chandler 219
Houston 169
Ho Chi Minh City 156
Ann Arbor 155
Hanoi 135
Hong Kong 135
Woodbridge 132
Seattle 119
San Jose 116
Wilmington 108
Cambridge 89
Beijing 83
Santa Clara 83
Dong Ket 82
Hefei 76
Princeton 76
Dublin 67
Jacksonville 66
Boardman 64
Los Angeles 54
New York 46
Abidjan 45
Nanjing 43
Lauterbourg 41
Amman 40
Westminster 36
Turin 35
Padova 34
Tokyo 27
Lomé 26
Berlin 24
Da Nang 24
Helsinki 23
Munich 22
Seoul 22
Bologna 21
Buffalo 21
Haiphong 20
Jinan 19
Saint Petersburg 19
Changsha 18
Council Bluffs 18
Frankfurt am Main 17
Shenyang 17
Milan 15
Nanchang 14
San Diego 14
São Paulo 14
Guangzhou 13
Redwood City 13
Abeokuta 12
Bremen 12
Brussels 12
Jiaxing 12
Bern 11
Can Tho 11
Florence 10
Mülheim 10
Phoenix 10
Zhengzhou 10
Chicago 9
Falkenstein 9
Hangzhou 9
Hải Dương 9
Sofia 9
Hebei 8
Norwalk 8
Tianjin 8
Warsaw 8
Dallas 7
Dearborn 7
London 7
Taizhou 7
Wuhan 7
Zanjan 7
Biên Hòa 6
Düsseldorf 6
Falls Church 6
Quito 6
Quận Bình Thạnh 6
San Francisco 6
Shanghai 6
Verona 6
Amsterdam 5
Bắc Ninh 5
Ha Long 5
Izumo 5
Johannesburg 5
Mahé 5
Redmond 5
Redondo Beach 5
Rome 5
Ankara 4
Atlanta 4
Brooklyn 4
Denver 4
Totale 4.550
Nome #
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 266
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 257
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 255
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 246
18 F-FDG PET in malignant lymphoma: significance of positive findings 245
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 239
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 232
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 221
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 217
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 212
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 211
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 209
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 209
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 203
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 203
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 197
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 195
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 194
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 175
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 172
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 172
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 171
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 168
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 164
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 164
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 163
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 163
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 162
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 160
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 158
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 153
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 150
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 148
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 145
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 138
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. 135
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 86
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 83
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 82
Gemcitabine 29
Totale 7.152
Categoria #
all - tutte 18.491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.491


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022916 194 21 65 117 57 47 17 48 21 47 180 102
2022/2023948 107 108 54 115 69 84 20 37 211 29 72 42
2023/2024195 13 44 8 27 15 51 5 10 5 8 2 7
2024/2025856 28 168 75 47 162 47 55 11 4 67 18 174
2025/20262.054 160 279 161 110 243 137 145 46 467 162 92 52
2026/202731 31 0 0 0 0 0 0 0 0 0 0 0
Totale 7.152